SCLERO.ORG is retiring 4-24-2021. Thank you for the memories! You'll still find us in the Wayback Machine, and we'll carry your stories in our hearts forever.
Scleroderma Newsroom
ISN News Manager: Jo Frowde
Media Stories
Scleroderma Archive
We maintain news archives for the most recent 3 years.
2020: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2021 - 2020 - 2019 - 2018

November 2020 Scleroderma News

Evaluation of Malignancy Risk in Scleroderma (SSc) by Antibody Profile. A close temporal relationship between onset of SSc and malignancy has been reported in patients with anti-RNA polymerase III antibody. PubMed, Br J Dermatol, 09/13/2020. (Also see Cancer)

Fatigue and its relationship with disease-related factors in patients with systemic sclerosis (SSc): a cross-sectional study. We recommend multidisciplinary approaches to evaluate and improve these parameters in the treatment of fatigue from the early period in SSc patients. PubMed, Turk J Med Sci, 09/15/2020. (Also see Fatigue)

Undifferentiated connective tissue disease at risk for systemic sclerosis (SSC): Which patients might be labeled prescleroderma? Predicting at onset which patients with Raynaud’s phenomenon are going to develop SSc over time has long been a research objective and still is an unaccomplished task. PubMed, Autoimmun Rev, 2020 Sep 14;102659. (Also see Undifferentiated Connective Tissue Disease)

Changes in mental health symptoms from pre-COVID-19 to COVID-19 among participants with systemic sclerosis from four countries: A scleroderma patient-centered intervention network (SPIN) cohort study. Anxiety symptoms, but not depression symptoms, increased dramatically during COVID-19 among people with a pre-existing medical condition. Journal of Psychosomatic Research, 10/03/2020. (Also see Anxiety and Attitude)

TL1A Promotes Lung Tissue Fibrosis and Airway Remodeling. Reagents that disrupt the interaction of TL1A with DR3 then have the potential to prevent deregulated tissue cell activity in lung diseases that involve fibrosis and remodeling. PubMed, J Immunol, 2020 Sep 21;ji2000665. (Also see Pulmonary Fibrosis)

Case Report: Scleroderma –associated thrombotic microangiopathy (TMA) in overlap syndrome of systemic sclerosis (SSc) and systemic lupus erythematosus (SLE). The occurrence of TMA leads to the deterioration of the prognosis of SSC-SLE overlap syndrome. PubMed, Medicine (Baltimore). (Also see Scleroderma in Overlap)

Machine learning integration of scleroderma (SSc) histology and gene expression identifies fibroblast polarisation as a hallmark of clinical severity and improvement. CD34 and aSMA stains describe distinct fibroblast polarisation states and may be useful biomarkers of clinical severity and improvement in diffuse SSc. PubMed, Ann Rheum Dis, 10/07/2020. (Also see Fibroblasts and Genetics)

Mycophenolate mofetil (MMF) for systemic sclerosis (SSC): drug exposure exhibits considerable inter–individual variation–a prospective, observational study. MMF–treated SSc patients exhibit considerable inter–individual variation in drug exposure. PubMed, Arthritis Res Ther, 2020 Oct 6;22(1):230. (Also see Immunosuppressants)

Current immunosuppressive and antifibrotic therapies of systemic sclerosis (SSc) and emerging therapeutic strategies. A better understanding of SSc pathophysiology has enabled the identification of numerous new therapeutic targets. PubMed, Expert Rev Clin Pharmacol, 10/02/2020. (Also see Immunosuppressants and Stem Cell (Bone Marrow) Transplantation)

Case Report: Hypertensive Emergency in a Woman with Systemic Sclerosis. We present a clinical case of scleroderma renal crisis with a typical presentation of hypertensive emergency and acute kidney injury. PubMed, High Blood Press Cardiovasc Prev, 10/01/2020. (Also see Kidney (Renal) Involvement)

Go to Scleroderma Medical News: October 2020

SCLERO.ORG was the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses from 1998 to 2021. It was a grassroots movement from the original Scleroderma from A to Z web site, which was founded by Shelley Ensz. We were a 501(c)(3) U.S.-based public charitable foundation. We closed this web site and our nonprofit agency in April 2021.

International Scleroderma Network (ISN)